

## Points of Comment to Reviewers

We would like to thank the reviewers for their input and appreciate the points raised within our manuscript. We have summarised their suggestions below and our response to these points.

### Reviewer 1:

01436308

1. "All the abbreviations should be defined accurately at their first instance". *Corrected within relevant abstract and introduction sections of manuscript.*
2. "Elevated uric in those with NAFLD": did the authors mean "uric acid is elevated in those with NAFLD" in the abstract? *Corrected now to "elevated uric acid levels in those with NAFLD"*
3. "An antioxidant and NOX inhibitor (figure 1A) or by silencing NOX4 (figure 1B)": The figure is not provided by the authors. – *Initial oversight and now edited.*
4. The expression of "in Hong-Kong (19.3%) and other Asian-Pacific countries ..." is inappropriate. The authors are advised to express this as follow: "in Hong-Kong, China (19.3%) and other Asian-Pacific countries or regions...". *Corrected as suggested.*
5. Please review all references to make sure they are complete and comply with the World Journal of Gastroenterology requirements. *Corrected to relevant WJG required format.*

### Reviewer 2:

00070897

The authors reviewed the proposed role of uric acid in the pathogenesis of non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis in open way, it is helpful for further investigation the relationship between uric acid and non-alcoholic fatty liver disease. *Many thanks for positive review.*

### Reviewer 3:

01555255

1. Introduction section: I suggest to report prevalence of high blood level of uric acid in NAFLD patients and the role of diet (PMID:30033779) *Included now as per suggestion.*

2. Discussion section: I suggest to briefly report the treatment options for this condition associated to NAFLD. *Briefly described lack of dedicated RCT and EASL recommendations*
3. Figure: a figure that summarize the pathogenic role of uric acid can be useful. *Included now as per suggestion.*
4. "Presentation: the text's style is not in line with the guidelines of the journal. Please revise it." – *Reviewed as per BPG guidelines and corrected accordingly.*

Reviewer 4:

00227403

"In this review/personal opinion the authors discussed on the potential relationship between uric acid and NASH. Reading carefully this work and reading part of the works cited in this review it appears that uric acid is only a component (among others) of NASH but it does not influence disease progression, it does not help in clinical management and it has not a significant relevance in therapeutic approach of NASH. Hence, to report a personal opinion on this association is not relevant in literature."

*We appreciate the thoughts of the reviewer and as a personal opinion piece it may indeed be better appreciated as a mini-review, which the publishers could consider. With respect, there is no other conclusive contemporary review paper of what is a significant area of interest within the hepatology community. Similarly, there are useful insights from animal works that uric acid amelioration may have consequent benefits and to this end this should be used to forward potential in man trials. We have again alluded to this aspect in our manuscript.*

Reviewer 5:

00007076

It would be better to focus the para "Evidence on NAFLF" by adding to the list of the studies a critical evaluation of what each study suggested. *Have included as suggested.*

The portion on lean-NAFLD needs to be improved by indicating the limits of the large studies reported. *Added new insights and some aspects on shortcomings*